u-PA与u-PAR在前列腺癌中的表达

EXPRESSION OF u-PA AND u-PAR IN PROSTATIC CANCER

①目的 探讨尿酸氧化酶型纤溶酶原激活物 (u PA)、尿酸氧化酶型纤溶酶原激活物受体 (u PAR)在前列腺癌 (Pca)中的表达及其意义。②方法 用免疫组化方法检测 37例Pca组织标本、19例前列腺增生症 (BPH)组织标本中u PA ,u PAR的表达。③结果 BPH组织中u PA ,u PAR表达均为阴性。低分化Pca组织中u PA ,u PAR阳性表达率明显高于中、高分化组 (P =0 .0 39,0 .0 2 5 ) ,Pca伴骨转移组织中u PA ,u PAR阳性表达率明显高于无骨转移组 (P =0 .0 0 16 ,0 .0 0 2 9)。④结论 u PA ,u PAR阳性表达与Pca细胞分级、转移有关 ,可以作为判断Pca恶性程度的指标之一。

Objective\ To study the correlation between expression of urokinase type plasminogen activator and its receptor (u PA,u PAR) in human prostatic cancer (Pca) as well as its significance.\ Methods\ An immunohistochemical method was used to detect u PA,u PAR in 37 cases of human Pca and 19 cases of benign prostatic hyperplasia (BPH). \ Results\ The rate of expression of u PA,u PAR in lower differentiated human Pca was significantly higher than that in higher differentiated group( P =0.039,0.025), and that of those with bone metastasis was significantly higher than that of those with none ( P =0.001 6, 0.002 9 ).\ Conclusion \ The expression of u PA,u PAR in human Pca might be a marker for invasive potential of the malignancy. [